KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma

Press/Media

Period16 Sep 2024

Media coverage

1

Media coverage

  • TitleKEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma
    Media name/outletBioSpace
    Country/TerritoryUnited States
    Date16/09/24
    URLct.moreover.com/?a=54794562271&p=1gw&v=1&x=sYaTgB3gR_eWuuywotkmiQ
    PersonsJosep Llovet
View all 1
View less